Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2, 2017. The report details a strategic regulatory milestone for ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The announcement focuses on the submission of regulatory applications to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for a new HIV maintenance regimen.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the period. The only specific financial figure disclosed relates to a one-time regulatory expense:
- R&D Expense Impact: A $130 million cost associated with a priority review voucher submitted to the FDA will be reported as an R&D expense in GSK's Q2 2017 Adjusted results.
Other financial metrics such as liquidity, margins, and total debt are not provided in this text.
Material Changes and Operational Updates
The primary material change reported is the advancement of GSK's HIV portfolio through the following actions:
- Regulatory Submissions: Filed applications for a single-tablet, two-drug regimen combining dolutegravir (Tivicay) and rilpivirine (Edurant) for the maintenance treatment of HIV-1 infection.
- Clinical Basis: Submissions are based on the SWORD studies (SWORD-1 and SWORD-2), which included over 1,000 patients previously suppressed on three- or four-drug regimens.
- Regulatory Acceleration: A priority review voucher was submitted with the US New Drug Application (NDA), targeting an FDA action date within six months of receipt.
Guidance, Outlook, and Risks
Management Commentary: ViiV Healthcare leadership emphasized a shift in the HIV treatment paradigm, moving from traditional three-drug regimens to a two-drug maintenance option to improve patient quality of life and adherence. The company views this as a potential "step change" in HIV treatment.
Outlook: The company anticipates a target action date of six months from the FDA following the submission of the priority review voucher.
Risks and Contingencies:
- Regulatory Risk: The two-drug regimen is currently investigational and not approved anywhere in the world; approval is not guaranteed.
- Safety Risks: The filing includes extensive safety information for the component drugs (Tivicay and Edurant), noting risks of hypersensitivity reactions, liver injury, depression, and drug interactions.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their 2016 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the impact of the $130 million priority review voucher cost on Q2 2017 Adjusted R&D expenses and earnings per share.
- Monitor the FDA's acceptance of the priority review voucher and the confirmation of the six-month target action date.
- Track the regulatory review timelines for both the EMA and FDA submissions for the dolutegravir/rilpivirine combination.
- Review the full safety data from the SWORD studies regarding viral resistance and long-term tolerability.
- Assess the competitive landscape for HIV maintenance therapies as the two-drug regimen moves toward potential approval.